These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 30324224)

  • 1. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
    Zhuang Y; Chen D; Sharma A; Xu Z
    AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.
    Putnam WS; Prabhu S; Zheng Y; Subramanyam M; Wang YM
    Trends Biotechnol; 2010 Oct; 28(10):509-16. PubMed ID: 20691488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-centric Comparability Assessment of Biopharmaceuticals.
    Blümel M; Cordoba-Rodriguez R; Carroll JA; Beardsley RL; Maggio F; Wylie D; Tsang V; Ehrick R; Francq BG; Pohl T; Taktak S; Spasoff A; Morrison A; Albarghouthi M
    J Pharm Sci; 2024 Jun; 113(6):1415-1425. PubMed ID: 38373591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment.
    Li Z; Du X; Wang YC
    Pharm Res; 2024 Jan; 41(1):13-27. PubMed ID: 37910341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical comparability study of recombinant monoclonal antibody therapeutics.
    Ambrogelly A; Gozo S; Katiyar A; Dellatore S; Kune Y; Bhat R; Sun J; Li N; Wang D; Nowak C; Neill A; Ponniah G; King C; Mason B; Beck A; Liu H
    MAbs; 2018; 10(4):513-538. PubMed ID: 29513619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality.
    Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-Based Approach for Analytical Comparability and Comparability Protocols.
    Iyer KR; Lequeux I
    PDA J Pharm Sci Technol; 2020; 74(5):563-570. PubMed ID: 32295861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.
    Vezér B; Buzás Z; Sebeszta M; Zrubka Z
    Curr Med Res Opin; 2016 May; 32(5):829-34. PubMed ID: 26808864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.
    Kretsinger J; Frantz N; Hart SA; Kelley WP; Kitchen B; Novick S; Rellahan B; Stranges D; Stroop CJM; Yin P; Gastens MH
    J Pharm Sci; 2019 Apr; 108(4):1442-1452. PubMed ID: 30528942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs].
    Saitoh S
    Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparability Considerations and Challenges for Expedited Development Programs for Biological Products.
    Schrieber SJ; Putnam WS; Chow ECY; Cieslak J; Zhuang Y; Martin SW; Hanson P; Maggio F; Rosado LAR
    Drugs R D; 2020 Dec; 20(4):301-306. PubMed ID: 32914381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
    Alt N; Zhang TY; Motchnik P; Taticek R; Quarmby V; Schlothauer T; Beck H; Emrich T; Harris RJ
    Biologicals; 2016 Sep; 44(5):291-305. PubMed ID: 27461239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparability assessments of process and product changes made during development of two different monoclonal antibodies.
    Lubiniecki A; Volkin DB; Federici M; Bond MD; Nedved ML; Hendricks L; Mehndiratta P; Bruner M; Burman S; Dalmonte P; Kline J; Ni A; Panek ME; Pikounis B; Powers G; Vafa O; Siegel R
    Biologicals; 2011 Jan; 39(1):9-22. PubMed ID: 20888784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future issues in the manufacturing and development of monoclonal antibodies.
    Kozlowski S; Swann P
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):707-22. PubMed ID: 16828921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.